Scientists have discovered that a hormone best known for reducing appetite may have another important job: protecting the liver from inflammation and scarring.
The finding could eventually help researchers develop better treatments for people with advanced fatty liver disease.
The hormone is called GDF15. It is naturally produced by the body, especially when cells are under stress, and previous research has shown that higher levels can reduce appetite by sending signals to the brain.
Because eating less can lead to weight loss, scientists have been interested in GDF15 as part of the body’s system for controlling food intake and energy balance.
The new research from McMaster University suggests its effects go well beyond body weight.
The study focused on metabolic dysfunction-associated steatohepatitis, or MASH. This is a serious form of fatty liver disease in which excess fat is accompanied by inflammation and damage to liver cells.
Fatty liver disease is closely linked with obesity, type 2 diabetes and other metabolic problems. In its early stages it may cause few or no symptoms, but continued inflammation can gradually produce scar tissue in the liver.
This scarring is called fibrosis. If it becomes severe, patients can develop cirrhosis, liver failure or liver cancer, making it especially important to stop inflammation before permanent damage becomes extensive.
Weight loss can improve fatty liver disease because it reduces the amount of fat stored in the liver. New medicines that produce substantial weight loss have therefore created important treatment opportunities, but liver inflammation may not disappear completely in every patient.
Researchers led by Gregory Steinberg and Dongdong Wang wanted to know whether GDF15 might influence liver disease independently of weight loss. They studied mouse models designed to reproduce important features of human MASH and used several laboratory methods to follow what happened after GDF15 became active.
The team found that GDF15 triggered a chain of signals beginning in the brain. Those signals traveled through the nervous system and ultimately increased the release of glucocorticoids, steroid hormones naturally made by the body.
Glucocorticoids help regulate the immune system, metabolism and the body’s response to stress. In this study, they helped calm inflammatory activity in the liver.
Most importantly, the liver benefits appeared even when GDF15 did not reduce food intake, body weight or liver fat. That finding suggests the hormone can directly influence the processes that drive liver injury rather than helping only because people or animals eat less.
The researchers also found signs that GDF15 slowed liver fibrosis. Using advanced methods to examine where genes were active inside liver tissue, they observed changes in liver cells and immune cells that were consistent with a less inflammatory and more protective environment.
This adds a surprising new dimension to GDF15. Earlier work from the McMaster team showed that the hormone can help maintain energy use during weight loss, while the new study suggests it also activates a brain-to-liver defense system.
The discovery could matter because inflammation is one of the hardest parts of advanced fatty liver disease to control. A future treatment that combines weight loss and lower liver fat with direct control of inflammation might offer stronger protection against worsening disease.
However, the results should not be interpreted as proof that GDF15 is ready to treat people with MASH. Much of the new work was performed in experimental mouse models, and biological effects seen in animals do not always produce the same benefits or safety profile in humans.
Researchers will need to determine whether this pathway works in people, how strongly it can reduce liver damage and whether activating it for long periods creates unwanted effects. Glucocorticoids themselves can cause significant problems when chronically elevated, so understanding how the pathway is controlled will be important.
Overall, the study is valuable because it separates GDF15’s liver effects from its better-known influence on appetite and weight. Rather than viewing the hormone simply as a weight-loss signal, the findings suggest it may be part of the body’s natural response to chronic liver injury.
The research was published in Cell Metabolism on August 10, 2026. If future human studies support the results, the work could open a new route toward treatments that protect the liver by attacking inflammation as well as excess fat.
If you care about liver health, please read studies that refined fiber is link to liver cancer, and the best and worst foods for liver health.
For more health information, please see recent studies about how to boost your liver naturally, and simple ways to detox your liver.
